19th European Society for Biomedical Research on Alcoholism Conference

8:00-9:00 Registration

Lecture Hall 1

9:00-9:30
Opening Ceremony

9:30-10:15
Plenary session 1. Epidemilogy of alcohol-related organ disease in Europe
Helena Cortez-Pinto, Lissbon, Portugal
Chairs: R. Stauber and P. Fickert, Graz, AUT

10:15-10:30 COFFEE BREAK

TOPIC Alcohol-related burden of disease: epidemiologic, economic and social implications (1)

10:30-11:50
Session 1. Stigma in people with alcohol use disorder (AUD) or alcohol-related liver disease (ARLD)
Chairs: A. Dhanda, Plymouth, UK; P. Carrieri, INSERM, Marseille, FRA

10:30-10:50
Stigma and psychosocial effects in alcohol use disorder and alcohol-related liver disease
G. Schomerus, Leipzig, GER

10:50-11:10
How to reduce stigma: a clinical and policy perspective
P. Carrieri, INSERM, Marseille, FRA

11:10-11:30
What can a hepatologist do to tackle stigma?
A. Dhanda, Plymouth, UK

11:30-11:50
Perspectives on stigma from people with lived experience of AUD and ARLD
Lesley Manning (on behalf of members of the South West Liver Buddies group), UK

11:50-12:10 COFFEE BREAK

TOPIC Alcohol-related burden of disease: epidemiologic, economic and social implications (2)

12:10-13:30
Session 2. New insights regarding individual and environmental factors associated with changes in alcohol use: population-based epidemiologic approaches
Chairs G. Airagnes, Paris, FRA; TBA

12:10-12:30
Bilateral relationships between cannabis and alcohol go mainly from cannabis to alcohol
J. Matta, Paris, FRA

12:30-12:50
Factors associated with self-reported changes in alcohol use among young adults during the COVID-19 pandemic: a comparative analysis between Canada and France
P.-J. Coulaud, Vancouver, CAN

12:50-13:10
Changes in alcohol use during the COVID-19 pandemic in health-students: The roles of other substance use and literacy in health
G. Airagnes, Paris, FRA

13:10-13:30
Atypical working hours and changes in alcohol use among workers from various sociodemographic backgrounds
N. Hamieh, Paris, FRA

13:30-14:30 LUNCH ESBRA ECI committee meeting

TOPIC Social cognition and problematic alcohol use

14:30-15:50
Session 3. Recent advances in the study of social cognition and problematic alcohol use
Chairs: A. Pabst, P. Maurage, Louvain, BEL

14:30-14:50
Acute effects of alcohol on empathy in heavy drinking young adults
L. Kumar, Pittsburgh, USA

14:50-15:10
Longitudinal relationships between empathy and alcohol-related outcomes in heavy drinkers
E. Claus, The Mind Research Network, USA

15:10-15:30
Alcohol use Disorder displays trait-related reductions in prosocial decision making
S. Jangard, Stockholm, SWE

15:30-15:50
Altered attention to facial features in patients with severe alcohol use disorder
A.Pabst, Louvain, BEL

15:50-16:10 COFFEE BREAK

TOPIC Altered attention to facial features in patients with severe alcohol use disorder
A. Pabst, Louvain, BEL

16:10-17:50
Session 4. Binge drinking during adolescence: Latest developments
Chairs: P Maurage, Louvain, BEL; TBA

16:10-16:30
Stress, cognition, and alcohol use during adolescence: does acute stress play a role in cognitive impairments associated with risky alcohol consumption?
S. Suarez, Louvain, BEL

16:30-16:50
Microbiome and cognitive alterations in young binge drinkers
C. Carbia, Cork, IRL & Louvain, BEL

16:50-17:10
Alcohol-specific memory inhibition training in binge drinkers: a double-blind randomized controlled trial examining alcohol use and craving levels
E. Lopez-Caneda, Minho, PRT

17:10-17:30
Abnormal organization of inhibitory control functional networks in future binge drinkers
TBA

17:30-17:50 COFFEE BREAK

TOPIC Genetic implications in alcohol-related organ damage

17:50-18:30
Session 5. Genetics of alcohol-related liver disease: risk factors, risk prediction and potential therapeutic approaches
Chairs: D. Seth, Sydney, AUS; M. Morgan, London, UK

17:50-18:10
Polygenic risk score for risk stratification in ALD
Tae-Hwi Schwantes-An, Indiana, USA

18:10-18:30
Genetic and Environmental risk factors for AUD, ALD and NAFLD
S. Romeo, Gothenburg, SWE & Catanzaro, IT

18:30-18:50
Genetic profiling as a gateway to therapeutic discovery in liver diseases
L. Valenti, Milano, IT

18:50-19:10
The emerging role of the microbiome in ALD therapy
D. Shawcross, London, UK

Lecture Hall 2

TOPIC Alcohol-related liver injury: role of dysregulated lipid metabolism

10:30-11:50
Session 6. New insights into mechanisms of deysregulated lipid metabolism and ist role in the progression of alcohol-associated liver disease
Chairs: C. Casey, Omaha, USA; M. McNiven, Rochester, USA

10:30-10:50
An ethanol-based disruption of the ubiquitin-proteasome transporter protein VCP induces hepatocyte steatosis by an accumulation of the LD-surface enzyme HSD17B13
M. McNiven, Rochester, USA

10:50-11:10
Role of long noncoding RNA H19 in regulation of lipid metabolism in alcohol associated liver disease
L. Gobejishvili, Louisville, USA

11:10-11:30
Host-derived 5S rRNA pseudogene transcripts are associated with inflammatory responses in alcohol-associated hepatitis
L. Nagy, Cleveland, USA

11:30-11:50
Is hepatic steatosis really a mandatory disease stage or just a bystander in alcohol-related liver disease?
S. Mueller, Heidelberg, GER

11:50-12:10 COFFEE BREAK

TOPIC Gut-Liver-Axis (1)

12:10-13:30
Session 7. Gut-liver interaction in alcohol-associated organ damage
Chairs: P. Thomes, Omaha, USA; C. Casey, Omaha, USA

12:10-12:30
Role of Intestinal Autophagy in the Pathogenesis of ALD
P. Thomes, Omaha, USA

12:30-12:50
Gut Barrier Impairment is Key Disease Driver in ALD
S. Chokshi, London, UK

12:50-13:10
Calcium Channels in the Intestinal Epithelium Play a Crucial Role in Alcohol-Induced Tissue Injury at the Gut-Liver and Gut-Brain Axis
R. Rao, Knoxville, USA

13:10-13:30
Role of Microbiota Dysbiosis and Leaky Gut in Alcohol-Induced Organ Damage
A. Keshavarzian, Chicago, USA

13:30-14:30 LUNCH

TOPIC Gut-Liver Axis (2)

14:30-15:50
Session 8. Role of intestinal microbiota, barrier dysfunction and autophagy for onset, progression and treatment of ALD
Chairs: I. Bergheim, Vienna, AUT; K. Ikejima, Tokyo, JPN

14:30-14:50
Gut-liver axis in ALD development: more than just the microbiome and dysbiosis
P. Stärkel, Saint-Luc, BEL

14:50-15:10
Modulation of the intestinal NO homeostasis as trigger of intestinal barrier dysfunction in the development of alcohol-related disease
A. Baumann, Vienna, AUT

15:10-15:30
Pharmaco-nutritional approaches to metabolic dysfunction-associated fatty liver disease
A. Uchiyama, Tokyo, JPN

15:30-15:50
The role of autophagy and nuclear proteins in the pathophysiology of steatohepatitis
S. Yamashina, Tokyo, JPN

15:50-16:10 COFFEE BREAK

TOPIC Gut-Liver-Brain Axis (1)

16:10-17:50
Session 9. Metabolomics as a new tool to investigate the gut-liver-brain axis and the treatment response in AUD
Chairs: P. de Timary, C. Carbia, Louvain, BEL & Cork, IRL

16:10-16:30
Untargeted and target lipidomics reveal sphingomyelins as a driver of small gut T cell apoptosis in alcohol use disorder (AUD) patients
P. Stärkel, Louvain, BEL

16:30-16:50
Comparison of metabolite profiles of persons with progressive ALD to persons with non-progressive ALD and healthy controls identify possible metabolic processes associated with progressive ALD
E. Puhakka, Kuopio/Joensuu, FIN

16:50-17:10
Gut microbiota-derived metabolites and their potential neuroactive properties, as a way to investigate the gut-brain axis in AUD patients
S. Leclercq, Louvain, BEL

17:10-17:30
Baseline metabolite profile could be useful for personalized medicine in AUD patients
O. Kärkkäinen, Kuopio/Joensuu, FIN

17:30-17:50 COFFEE BREAK

TOPIC Mechanisms of cholestasis in alcohol-related liver disease

17:50-18:30
Session 10. Key note lecture 1. Mechanisms of cholestasis in alcohol-related liver disease
P. Fickert, Graz, AUT
Chairs: M. Trauner, Vienna, AUT; M. Wagner, Graz, AUT

Lecture Hall 3

TOPIC Management of alcohol-use disorder (1)

10:30-11:50
Session 11. Treatment of Alcohol Use Disorder: Safety and Efficacy of Precision Medicine in Selected Patients
Chairs: J. Chick, Castle Craig, UK; G. Addolorato, Rome, IT

10:30-10:50
Why we need new anti-craving medications
H. Alho, Helsinki, FIN

10:50-11:10
Subgroups of Alcohol Dependence and Their Special Treatment
O. Lesch, Vienna, AUT

11:10-11:30
New Approaches in the Treatment of Alcohol Dependence
B. Johnson, Miami, USA

11:30-11:50
Treatment of AUD in patients with different severity of liver disease
G. Addolorato, Rome, IT

11:50-12:10 COFFEE BREAK

TOPIC Management of alcohol-use disorder (2)

12:10:00-13:30
Session 12. Sodium oxybate for the treatment of alcohol dependence: results from an international clinical development and research project and perspectives
Chairs: O. Lesch, Vienna, AUT; W. van den Brink, Amsterdam, NL

12:10-12:30
Sodium oxybate for the treatment of alcohol use disorder: well-tolerated over 30+ years of clinical use
H. Walter, Medical University of Vienna, AUT

12:30-12:50
Sodium oxybate for the treatment of alcohol withdrawal syndrome: results from two Phase 3 randomized, double-blind, active-controlled trials
O. Lesch, Vienna, AUT

12:50-13:10
Sodium oxybate for the maintenance of abstinence in alcohol dependent patients: results from a Phase 3 international, multicenter, randomized, double-blind, placebo-controlled trial
W. van den Brink, Amsterdam, NL

13:10-13:30
The effect of population severity and treatment duration on sodium oxybate efficacy in the maintenance of abstinence in alcohol dependent patients
J. Guiraud, Amsterdam, NL

13:30-14:30 LUNCH

TOPIC Management of alcohol-use disorder (3)

14:30-15:50
Session 13. How to improve cognitive abilities to favor treatment outcome? New perspective and innovative tools
Chairs: A. Pitel, Caen, FR; P. Maurage, Louvain, BEL

14:30-14:50
Cognitive training and remediation for substance use disorders
A Verdejo-Garcia, Monash University, AUS

14:50-15:10
Mindfulness-based relapse prevention for drinking reductions
K. Witkiewitz, Albuquerque, USA

15:10-15:30
Preventing relapse in alcohol disorder using sensori-motor EEG-neurofeedback training: an event-related potentials study
C. Dousset, Brussels, BEL

15:30-15:50
The use of Virtual reality and 360° immersive videos to study and treat alcohol abuse and addiction
E. Quertemont, Liege, BEL

15:50-16:10 COFFEE BREAK

TOPIC The role of the nucleus of the amygdala (CeA) for regulation of behavioural dysfunctions related to alcohol exposure

16:10-17:50
Session 14. Central nucleus of the amygdala and alcohol use disorder: Perspectives from studies in mice to humans
Chairs: S. C. Pandey, Chicago, USA; K. Radwanska, Warsaw, POL

16:10-16:30
Innate immune-related mechanisms in AUD: a view from the tipsy amygdala synapses
M. Roberto, La Jolla, USA

16:30-16:50
A central amygdala molecular mechanism in punishment-resistant alcohol self-administration
E. Domi, Linköping, SWE and Camerino, IT

16:50-17:10
Epigenomic editing in the central amygdala ameliorates adult anxiety and drinking after adolescent alcohol exposure
S. C. Pandey, Chicago, USA

17:10-17:30
Arc controls alcohol relapse by a central amygdala mechanism
K. Radwanska, Warsaw, POL

17:30-17:50 COFFEE BREAK

TOPIC Young Investigators at the Medical University of Graz

17:50-18:30
Session 15. The role of fibroblast growth factor (FGF 19) in alcohol-related organ disease
Chairs: J. Wagner-Skacel, M. Wagner, Graz, AUT

17:50-18:10
The hormone FGF21 stimulates water drinking in response to ketogenic diet and alcohol
M. Wagner, Graz, AUT

18:10-18:30
FGF21 and personality functioning: A potential marker of abstinence
J. Wagner-Skacel, Graz, AUT

18:30-18:50
Neuropeptid Y and FGF21 in the gut-liver-brain axis
A. Farzi, Graz, AUT

18:50-19:10
FGF21 supresses alcohol consumption through an amygdalo-striatal circuit
A. Horvath, Graz, AUT

19:20-23:00 Social programme: Bus transfer to the barbecue evening at the mountain hut „Latschen-Hütte“, Teichalm

Lecture Hall 1

9:00 – 9:45
Plenary Session 2. Mallory-Denk bodies and hepatocellular ballooning. Historical perspectives, causes and consequences of protein misfolding in steatohepatitis
H. Denk, Graz, AUT
Chairs: C. Lackner, K. Zatloukal, Graz, AUT

9:45-10:00 COFFEE BREAK

TOPIC Alcohol and carcinogenesis

10:00-11:20
Session 16. New paradigms in alcohol-associated carcinogenesis and tumor progression
Chair: A. Petrosyan, Omaha, USA; TBA

10:00-10:20
P53-destabilizing protein recruits NOTCH to mitochondria to reprogram liver tumor-initiating stem-like cells induced by alcohol
K. Machida, Los Angeles, USA

10:20-10:40
Adolescent- and Adult-initiated Alcohol Exposure in Mice Differentially Promote Tumorigenesis and Metastasis of Breast Cancer
J. Luo, Iowa City, USA

10:40-11:00
The role of alcohol-induced Golgi disorganization and ER stress in the metastatic potential of prostate tumor
A. Petrosyan, Omaha, USA

11:00-11:20
Mechanisms of chronic Alcohol exposure induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal
A. Courtois, Amiens, FRA

11:20-11:40 COFFEE BREAK

TOPIC Alcohol-related multisystemic organ injury

11:40-13:00
Session 17. The multisystemic impact of unhealthy alcohol use; immune, metabolic, and neuropathological consequences

11:40-12:00
Alcohol promotes Alzheimer’s disease progression through neuroinflammation and metabolic dysfunction
L. Coleman, Chapel Hill, USA

12:00-12:20
Contribution of alcohol associated metabolic instability to aging comorbidities
P.E. Molina, New Orleans, USA

12:20-12:40
Alcohol impact on gut-brain axis in Parkinson
A. Keshavarzian, Chicago, USA

12:40-13:00
Alcohol-induced suppression of hepatocyte innate immunity; disrupts parenchymal and non-parenchymal cell crosstalk and exacerbates viral pathogenesis
N. Osna, Omaha, USA

13:00-14:00
LUNCH ESBRA Early-career investigators committee: Launch of mentorship program

TOPIC Young investigators at the Medical University of Vienna

14:00-15:30
Session 18. Early career investigators symposium
Chairs: D. König-Castillo, A. Kalenböck, Vienna, AUT

14:00-14:20
Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis
B. S. Hofer, Vienna, AUT

14:20-14:40
Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice
T. Hendrikx, Vienna, AUT

14:40-15:10
Brain iron overload and thiamine deficiency – a key pathway to explain and prevent cognitive decline in alcohol use disorder?
S. Listabarth, Vienna, AUT

15:10-15:30
Dissociative symptoms of patients with alcohol use disorder undergoing a qualitative study
S. Steirer, Vienna, AUT

15:30-15:50 COFFEE BREAK

TOPIC Alcohol-induced progression to end-stage liver disease

15:50-17:10
Session 19. Alcohol-induced progression to end-stage liver disease
Chairs: N. Osna, K. Kharbanda, Omaha, USA

15:50-16:10
Novel translational aspects of hepatic iron accumulation in heavy drinkers
S. Müller, Heidelberg, Germany

16:10-16:30
Causes and consequences of IL-17-Act1 signaling in mouse hepatocytes
T Kisseleva, La Jolla, CA, USA

16:30-16:50
Pro-fibrotic activation of hepatic stellate cells by engulfment of hepatocyte-derived apoptotic bodies generated in the context of HIV infection in response to ethanol metabolites
N. Osna, Omaha, USA

16:50-17:10
Overview on clinically relevant ex-vivo models of ALD including precision-cut liver slices and liver organoids
S. Chokshi, London, UK

17:10-17:30 COFFEE BREAK

TOPIC Albumin & ALD

17:30-18:50
Session 20. Role of albumin in alcohol-related liver disease
Chairs: P. Caraceni Bologna, Italy, R. Stauber, Graz, AUT

17:30-17:50
Structural damage of albumin and alterations of albumin binding function in ALD
K. Oettl, Graz, AUT

17:50-18:10
The concept of effective albumin concentration in chronic liver failure
P. Caraceni, Bologna, IT

18:10-18:30
Molecular adsorbents recirculating system (MARS) in severe alcohol-related hepatitis
M. Kukla, Cracow, POL

18:30-18:50
Hepalbin-based extracorporeal liver support: first results
J. Stange, Rostock, GER

Lecture Hall 2

TOPIC Histology of alcohol-related liver disease

10:00-11:20
Session 21. Histological features of alcohol-related liver disease and implications for clinical management
Chairs: D. Tiniakos, Athens, GRC; C. Lackner, Graz, AUT

10:00-10:20
Histological features of alcohol-related liver disease and differential diagnosis
S. Sygulla, Graz, AUT

10:20-10:40
Histologic grading and staging of alcohol-related liver disease and implications for clinical management
F. Sarocchi, Graz, AUT

10:40-11:20
Key note lecture 2. Digital assisted image analysis – emerging morphologic methods of tissue analysis. Potential impact and pitfalls
 D. Tiniakos, Athens, GRC; Chairs: H. Denk and K. Zatloukal, Graz, AUT

11:20-11:40 COFFEE BREAK

TOPIC Noninvasive assessment of liver fibrosis in alcohol related liver disease

11:40-13:00
Session 22. Noninvasive assessment of liver fibrosis in alcohol related liver disease
Chairs: I. Sporea, Timisoara, Romania; S. Mueller, Heidelberg, GER

11:40-12:00
Biological tests in ALD assessment
A. Popescu, Timisoara, RO

12:00-12:20
The place of elastography in ALD
I. Sporea, Timisoara, RO

12:20-12:40
How can we screen the ALD patients for liver fibrosis?
S. Mueller, Heidelberg, GER

12:40-13:00
Non-invasive assessment of portal hypertension in patients with ALD
I. Grgurevic, Zagreb, HRV

13:00-14:00 LUNCH

TOPIC Management of alcohol-related liver disease: The patients perspective

14:00-15:30
Session 23. Patient Centered Management of compensated alcohol-related liver disease: Current status and unmet needs
Chairs: H. Stefanescu, Cluj-Napoca, RO; J. Altamirano, Barcelona, ESP

14:00-14:20
What does a patient with ARLD expect from the healthcare system? ELPA representative / recording of Horia Stefanescu interviewing a patient

14:20-14:40
Individual and societal determinants of ARLD screening
M. Ventura Cots, Barcelona, ESP

14:40-15:10
Secondary prevention of ARLD in the Baveno VII era
B. Procopet, Cluj-Napoca, RO

15:10-15:30
Integrated outpatient care systems for ARLD patients
J. Altamirano, Barcelona, ESP

15:30-15:50 COFFEE BREAK

TOPIC Management of alcohol-related liver disease (1)

15:50-17:10
Session 24. Management of alcohol-related liver disease – overview
Chairs: S.G. Rodrigues, Bern, CH; M. Thiele, Odense, DK

15:50-16:10
Optimizing the management of Alcohol Use Disorder in patients with liver disease
O. Secara, Bern, CH

16:10-16:30
How to best identify and stage liver fibrosis and risk of liver-related events?
M Thiele, Odense, DK

16:30-16:50
Advanced Alcohol-related Liver Disease – managing the failing liver
S G. Rodrigues, Bern, CH

16:50-17:10
Liver Transplantation in the ArLD: challenging old paradigms and shedding light on novel aspects
C. Becchetti, Milano, IT

17:10-17:30 COFFEE BREAK

TOPIC Management of alcohol-related liver disease (2)

17:30-18:50
Session 25. Alcohol-related liver disease: what is new?
Chairs: C. Moreno, Brussels, BEL; C. Lackner, Graz, AUT

17:30-17:50
Strategies to identify in clinical practice alcohol-related liver disease patients before decompensated stage
E. Pose, Barcelona, ESP

17:50-18:10
How to define and manage patients with alcohol-related liver disease and metabolic syndrome?
H. Hagström, Stockholm, SWE

18:10-18:30
When to perform a liver biopsy in patients with alcohol-related liver disease?
R. Stauber, Graz, AUT

18:30-18:50
Severe alcohol-associated hepatitis: current management and future pipeline
P. Mathurin, Lille, FRA

Lecture Hall 3

TOPIC Joint ESBRA-JMSAAS meeting

10:00-11:20
Session 28. Alcohol-related diseases: From brain to liver function
Chairs: S. Mueller, Heidelberg, GER; K. Ikejima, JPN

10:00-10:20
Survey of the relationship between alcohol -related cognitive dysfunction and cerebral blood flow
T. Shirasaka, Sapporo, JPN

10:20-10:40
International cooperation in treatment of substance use disorders: The INTREPRET study in the Philippines
T. Harada, Tsukuba, JPN

10:40-11:00
Title: TBA.
A. Riva, London, UK

11:00-11:20
Targeted reprogramming of inflammatory macrophages using prednisolone-loaded nanoliposomes attenuates alcohol-associated liver diseases
R. Bansal, Twente, Enschede, NL

11:20-11:40 COFFEE BREAK

TOPIC Free oral presentations

11:40-13:00
Session 27. Free oral presentation (1)
Chairs: TBA

11:40-12:00
Free oral presentation

12:00-12:20
Free oral presentation

12:20-12:40
Free oral presentation

12:40-13:00
Free oral presentation

13:00-14:00 LUNCH

TOPIC Gut-Liver-Brain Axis (2)

14:00-15:30
Session 26: Brain Dysfunction in Alcohol-Related liver disease
Chairs: S. Chokshi, A. Hadjihambi, London, UK

14:00-14:20
No safe level of alcohol consumption for brain health
A. Topiwala, London, UK

14:20-14:40
Abnormal oxygen homeostasis as a major driver of alcohol and liver disease induced brain dysfunction
A. Hadjihambi, London, UK

14:40-15:10
Hepatic Encephalopathy: is it truly reversible following liver transplantation?
N. Weiss, London UK

15:10-15:30
Faecal Microbiota Transplant: A new avenue in treating the neurological manifestations of alcohol-related chronic liver failure
D. Shawcross, London, UK

15:30-15:50 COFFEE BREAK

TOPIC Nordman Award

15:50-17:10
Session 29. Bright Sparks in European alcohol research & ESBRA Nordmann award ceremony: Awardees of ESBRA travel fellowship
Chair: E. Palma, London, UK; ECIC Chair

15:50-16:00
Awardee 1

16:00-16:10
Awardee 2

16:10-16:20
Awardee 3

16:20-16:30
Awardee 4

16:30-16:40
Awardee 5

16:40-17:10
Nordman award: Lecture and award ceremony

17:10-17:30 COFFEE BREAK

TOPIC Alcohol and bone inury

17:30-17:50
Session 30. Key-note lecture 3: Overview on compartment and cell-specific alcohol effects on bone involving oxidative-stress dependent and independent mechanisms and acetate
M. Ronis, New Orleans, USA

Lecture Hall 1

9:00 – 9:45
Plenary session 3. DEBATE. Emerging terminologies in fatty liver diseases: NAFLD, ALD and MAFLD. An update on the current controversy
P. Mathurin, Lille, FRA; TBA;
Chair: C Moreno, Brussels, BEL

9:45-10:00 COFFEE BREAK

TOPIC Alcohol-related inflammation and the brain

10:00-11:20
Session 31. Contribution of inflammatory mechanisms to alcohol-related brain abnormalities: a translational approach
Chairs: P. De Timary, Louvain, BEL, A. Pitel, Caen, FRA

10:00-10:20
Exploring the role of x-binding protein-1 (XBP1) in the gut-brain axis during alcohol-related liver disease
C. Sanz-Garci­a, Madrid, ESP

10:20-10:40
Investigating the evolution and the links between systemic inflammation, behavioral symptoms and brain structure during early alcohol cessation in alcohol use disorders
G. Petit, Louvain, BEL

10:40-11:00
Progression of microstructural alterations in the brain during early alcohol abstinence: neurobiological substrates, inflammation and therapeutic targets
M. Selim, Alicante, ESP

11:00-11:20
Different inflammatory pathways in severe alcohol use disorder
L. Lebedel, Caen, FRA

11:20-11:40 COFFEE BREAK

TOPIC GABAB Receptor and alcohol use disorder

11:40-13:00
Session 32: GABAB Receptor and Alcohol Use Disorder: Preclinical and Clinical Update
Chairs: R. Agabio, Cagliari, IT; M. Naassila, Amiens, FRA

11:40-12:00
Sex-related difference in the efficacy of baclofen enantiomers on ethanol self-administration and dopamine transmission in rats
J. Jeanblanc, Amiens, FRA

12:00-12:20
Suppressing effects of KK-92A, a novel positive allosteric modulator of the GABAB receptor, on alcohol drinking and self-administration in alcohol-preferring rats
G. Colombo, Cagliari, IT

12:20-12:40
Baclofen and alcohol use disorder: Results from the latest Cochrane meta-analysis
R. Agabio, Cagliari, IT

12:40-13:00
Baclofen in alcohol use disorder: Data provided by the French „Temporary Recommendation for Use“ 2014-2017 cohort
B. Rolland, Lyon, FRA

Lecture Hall 2

TOPIC Alcohol and heart disease

10:00-11:20
Session 33. Alcohol-related heart disease
Chairs: P. Rainer, D. Scherr, Graz, AUT

10:00-10:20
Holiday heart: Alcohol-related atrial fibrillation
D. Scherr, Graz, AUT

10:20-10:40
Alcohol-related cardiomyopathy
P. Rainer, Graz, AUT

10:40-11:00
Cirrhotic cardiomyopathy
S. Möller, Copenhagen, DK

11:00-11:20
Cirrhose cardiaque
TBA

11:20-11:40 COFFEE BREAK

TOPIC Korsakow´s Syndrome update

11:40-13:00
Session 34. Intergrative approach to Korsakoff´s syndrome: an old story revisited
Chair: A. Pitel, Caen, FRA

11:40-12:00
Going downhill? Differences between patients with a „uncomplicated“ alcohol use disorder, alcohol-related cognitive impairments, and Korsakoff´s syndrome on cognitive and neuropsychiatric measures
Y. Rensen, Venray, NL

12:00-12:20
Distinct sleep alterations in alcohol use disorder patients with and without Korsakoff`s syndrome
A. Laniepce, Rouen, FRA

12:20-12:40
Thiamine transport and genetics: recent evidences of increased biological vulnerability to alcohol related Wernicke-Korsakoff syndrome
I. Guerrini, London, UK

12:40-13:00
Looking beyond alcohol-related neurocognitive disorders: neuropsychological and brain specificities of Korsakoff’s syndrome compared to Alzheimer’s disease
C. Soussi, Caen, FRA

Lecture Hall 3

TOPIC Free oral presentations

10:00-11:20
Session 35. Free oral presentation (2)
Chairs: TBA

10:00-10:20
Free oral presentation

10:20-10:40
Free oral presentation

10:40-11:00
Free oral presentation

11:00-11:20
Free oral presentation

11:20-11:40 COFFEE BREAK

TOPIC Intensive care

11:40-13:00
Session 36: Emergencies in alcohol-related disorders
Chairs: TBC

11:40-12:00
Prevention and treatment of acute alcohol withdrawal 
B. Vyssoki, Vienna, AUT

12:00-12:20
Hyponatriemia
W. Ribitsch, Graz, AUT

12:20-12:40
The trajectory of acute hepatic decompensation in ALD
TBA

12:40-13:00
Management of ACLF in ALD
L. Kramer, Vienna, AUT

13:00-13:30
Closing remarks & Fare well